中国临床药理学与治疗学2017，Vol.22Issue(2)：228-232,5.
肿瘤免疫检查点抑制剂个体化用药策略研究进展
Research progress of personalized medicine for immune checkpoint blockades
摘要
Abstract
Immune checkpoint blockades,which release the brake of immune system to enhance anti-cancer immune response,stand out in the cancer immunotherapy field due to their remarkable and long-lasting effect.However,the overall response rate for currently proved immune checkpoint inhibitors is only about 10％-40％.How to predict patients' outcome of these drugs has becoming the crucial focus in clinical.Three major components considered as the key to describe the cancer-immune interaction in immune checkpoint therapy will be discussed in this review.关键词
免疫治疗/免疫检查点抑制剂/个体化医学/PD-1/PD-L1抑制剂Key words
S immunotherapy/immune checkpoint blockades/personalized medicine/PD-1/PD-L1 inhibitors分类
医药卫生引用本文复制引用
王韦力,廖萍,许标波,周成芳,谢商宸,沈冬亚,贺毅憬,Howard L.Mcleod..肿瘤免疫检查点抑制剂个体化用药策略研究进展[J].中国临床药理学与治疗学,2017,22(2):228-232,5.基金项目
国家自然科学基金项目(81403022) （81403022）
